Life Sciences in October 2026: Faster Trials, Fake Peptides and AI Rulebooks

From mid-September to mid-October 2026, life sciences regulators made one thing plain: they are working to speed up legitimate innovation and shut down illegitimate supply at the same time. Our Trends Radar tracked official developments across all nine RegASK regions, and three trends stood out. First, regulators are racing to get clinical trials started sooner, with new pilots and pathways in the U.S., Europe, the U.K., Saudi Arabia and Brazil. Second, authorities on 6 continents moved against counterfeit and unapproved weight-loss peptides, escalating warnings to bans, seizures and criminal charges. Third, adaptive and generative AI in medical devices is getting its first dedicated rulebooks. For global teams, the gap between the fastest and slowest regulatory systems, and between the legal and illegal market, is becoming a strategic variable. 

The Race to Start Clinical Trials Sooner 

First-in-human trials in the U.S. can currently take up to 2 years to get started, according to the FDA [1]. That kind of lag has become a competitive issue, and regulators know it. Across this window, our Trends Radar tracked about 20 official developments on clinical trial speed, early development and expedited pathways in 8 jurisdictions, spanning North America, Europe, the Middle East and Latin America. The mechanisms differ, but the goal is the same: earlier engagement, fewer surprises and faster starts. 

The FDA opened its Expedited IND Pilot, which pairs sponsors with qualified research institutions and tests rolling review during the pre-IND phase; it expects 8 to 10 pairs and accepts applications until 30 October 2026 [1]. It also opened year 5 of its CMC Development and Readiness Pilot for programs on accelerated clinical timelines [2] and launched a Rare Disease Framework Initiative, noting that only about 5% of rare conditions have an FDA-approved treatment [3]. In Europe, EMA confirmed that its pre-submission advice pilot for clinical trial applications becomes permanent in January 2027 [4], while its Management Board flagged that the proposed Biotech Act would affect about 70% of current Clinical Trials Information System functionality, with first changes to the Clinical Trials Regulation possible in early 2028 [5]. The U.K.’s MHRA committed to halve the initial assessment of qualifying Phase 1 trials to 14 days and cut premium scientific advice from 90 to 45 days [6]. Saudi Arabia’s SFDA and the Saudi NIH launched 5 clinical trial initiatives, including a clinical trials reliance pathway [7], and Brazil’s ANVISA invited up to 8 new-medicine projects, 6 of them prioritized for national developers, into a regulatory advice program in which the agreed trial design becomes binding [8]. 

For sponsors, the first trial site is becoming a strategic choice rather than a default. Jurisdictions are competing on speed, predictability or both, and some, like Brazil, explicitly prioritize local developers [8]. Early agreements also carry more weight later: ANVISA’s binding design commitments [8] and the FDA’s rolling pre-IND review [1] both reward sponsors that invest in early dialogue. Teams that compare pathways across markets before locking their development plan can start sooner and avoid redesigning trials midstream. 

References 

1. FDA launches Expedited IND Pilot, begins accepting applications (15 Sep 2026): https://www.fda.gov/news-events/press-announcements/fda-launches-expedited-ind-pilot-begins-accepting-applications 

2. FDA Chemistry, Manufacturing, and Controls Development and Readiness Pilot (CDRP) Program (updated 18 Sep 2026): https://www.fda.gov/drugs/pharmaceutical-quality-resources/chemistry-manufacturing-and-controls-development-and-readiness-pilot-cdrp-program 

3. FDA launches Rare Disease Framework Initiative (14 Oct 2026): https://www.fda.gov/news-events/press-announcements/fda-launches-rare-disease-framework-initiative-develop-holistic-fit-purpose-framework-rare-disease 

4. EMA Clinical trial applications advice pilot becomes permanent (8 Oct 2026): https://www.ema.europa.eu/en/news/clinical-trial-applications-advice-pilot-becomes-permanent 

5. EMA Management Board: highlights of September 2026 meeting (1 Oct 2026): https://www.ema.europa.eu/en/news/ema-management-board-highlights-september-2026-meeting 

6. MHRA 2030 strategy to modernise patient-centred regulation for the era of AI and personalised medicines (14 Oct 2026): https://www.gov.uk/government/news/mhra-2030-strategy-to-modernise-patient-centred-regulation-for-the-era-of-ai-and-personalised-medicines 

7. SFDA and Saudi NIH launch 5 initiatives to advance clinical trials (7 Oct 2026): https://www.sfda.gov.sa/en/news/19734 

8. ANVISA selects new-medicine projects for regulatory advice initiative, Call Notice No. 7/2026 (24 Sep 2026): https://www.gov.br/anvisa/pt-br/assuntos/noticias-anvisa/2026/anvisa-seleciona-projetos-de-novos-medicamentos-para-iniciativa-de-aconselhamento-regulatorio 

Regulators Close In on the Gray Market for Weight-Loss Peptides 

Demand for GLP-1 medicines has created a parallel market: counterfeit pens, unregistered imports and investigational peptides sold online, often labeled “for research use only.” Between mid-September and mid-October 2026, that market drew a coordinated response. Our Trends Radar logged about 14 official actions on falsified and unapproved weight-loss peptides in 11 jurisdictions across 6 regions, one of the widest geographic footprints of any life sciences theme this month. The direction is unmistakable: from consumer warnings to bans, seizures and prosecutions. 

Much of the activity centered on retatrutide, an investigational weight-loss peptide not approved anywhere. Argentina’s ANMAT banned the use, sale, advertising and distribution of any product declaring it, including online sales [1], and Brazil’s ANVISA reported seizing more than 1,000 irregular products at Rio’s Galeão Airport, including 572 units of retatrutide and 347 of tirzepatide [2]. Australia’s TGA found that a product sold as retatrutide actually contained undeclared semaglutide at about 8 times the approved level, following a serious adverse event [3], and began Federal Court proceedings over unlawful peptide advertising [4]. Singapore’s HSA warned that retatrutide and cagrilintide bought online have been linked to reports of anaphylaxis [5], and Saudi Arabia’s SFDA referred online sellers of unregistered peptides for prosecution, with penalties of up to SAR 5 million and 5 years’ imprisonment [6]. In the U.K., MHRA and police seized more than 12,000 fake retatrutide and tirzepatide pens worth about £2 million [7], and in the U.S. an FDA criminal investigation led to charges over counterfeit Ozempic sourced from China [8]. Regulators are also tightening the legitimate channel: ANVISA brought retained prescriptions, including GLP-1 receptor agonists, under electronic control from 30 September [9], and South Africa’s SAHPRA issued its first guideline on the quality and clinical aspects of synthetic peptide medicines [10]. 

For manufacturers of authorized GLP-1 and peptide products, this is more than a brand-protection issue. Counterfeit and unapproved products generate adverse events that can reach safety databases and headlines under a genuine product’s name [3], and regulators increasingly expect companies to support enforcement with authentication and market intelligence. For telehealth providers, compounders, wellness brands and online marketplaces, the message is equally clear: peptides promoted for weight loss, muscle gain or skin care are being treated as medicines, and advertising them is now an enforcement priority [4][6]. Monitoring enforcement actions across markets is the fastest way to spot where the next ban or seizure is likely to land. 

References 

1. ANMAT prohibits products declaring retatrutide, Disposition 6140/26 (24 Sep 2026): https://www.argentina.gob.ar/noticias/anmat-prohibe-productos-que-declaren-contener-retatrutide-o-retatrutida 

2. ANVISA More than 1,000 irregular products seized at Galeão Airport (22 Sep 2026): https://www.gov.br/anvisa/pt-br/assuntos/noticias-anvisa/2026/mais-de-1000-produtos-irregulares-apreendidos-no-aeroporto-do-galeao 

3. TGA tests counterfeit retatrutide product following serious adverse event report (14 Sep 2026): https://www.tga.gov.au/safety/safety-monitoring-and-information/safety-alerts/tga-tests-counterfeit-retatrutide-product-following-serious-adverse-event-report 

4. TGA Former company and directors behind BioV8 to face court for alleged unlawful advertising of peptides (28 Sep 2026): https://www.tga.gov.au/news/media-releases/former-company-and-directors-behind-biov8-face-court-alleged-unlawful-advertising-peptides 

5. HSA Singapore Risks of obtaining prescription medicines and unapproved injectable peptides through unauthorised channels (25 Sep 2026): https://www.hsa.gov.sg/announcements/risks-of-obtaining-prescription-medicines-unauthorised-channels/ 

6. SFDA takes action against websites and online accounts marketing unregistered peptides (29 Sep 2026): https://www.sfda.gov.sa/en/news/19668 

7. MHRA Counterfeit weight loss pens worth £2 million seized by MHRA and West Midlands Police (15 Oct 2026): https://www.gov.uk/government/news/counterfeit-weight-loss-pens-worth-2-million-seized-by-mhra-and-west-mids-police 

8. FDA investigation leads to charges against two Indian nationals involved in transnational counterfeit drug distribution scheme (29 Sep 2026): https://www.fda.gov/news-events/press-announcements/fda-investigation-leads-charges-against-two-indian-nationals-involved-transnational-counterfeit-drug 

9. ANVISA Start of new SNCR stage: what changes from 30 September (21 Sep 2026): https://www.gov.br/anvisa/pt-br/assuntos/noticias-anvisa/2026/inicio-de-nova-etapa-do-sncr-o-que-muda-a-partir-de-30-de-setembro 

10. SAHPRA Guideline on the Quality and Clinical Aspects of Synthetic Peptides, SAHPGL-CRO-04 v1 (13 Oct 2026): https://www.sahpra.org.za/document/guideline-on-the-quality-and-clinical-aspects-of-synthetic-peptides/ 

Generative AI Gets Its First Device Rulebooks 

Software that keeps learning after it reaches the market has always strained device rules written for fixed products. Generative AI strains them further. Between mid-September and mid-October 2026, our Trends Radar tracked about 11 AI-device actions from regulators in Japan, the U.K., the U.S., Singapore, China and Taiwan, along with WHO and the international forum where device regulators coordinate. For the first time, several of them are drafting rules written specifically for adaptive and generative systems. 

Japan’s PMDA published draft review points for medical devices that use generative AI, open for comment until 17 March 2027 [1]. The U.K. government accepted all 44 recommendations of the National Commission into the Regulation of AI in Healthcare: MHRA will publish draft guidance on managing changes to adaptive AI devices by December 2026, consult on how AI devices are qualified and classified in 2027, and select the first wave of its AI Airlock post-market sandbox in November [2]. MHRA’s 2030 strategy adds a dedicated centre for AI and digital health [3]. In the U.S., the FDA denied a petition to exempt radiology computer-aided detection, diagnosis and triage software from 510(k) clearance, keeping premarket review in place [4]. The WHO added AI-based computer-aided detection software for tuberculosis screening to its prequalification program, its first digital health product class [5]. Singapore’s HSA reported that IMDRF delivered an AI and machine learning technical framework for harmonized oversight of AI-enabled devices during Singapore’s chairmanship [6], and China’s NMPA signed a letter of intent with MHRA that covers, among other areas, regulation of AI-enabled medical devices [7]. 

Two signals matter for device and software manufacturers. First, oversight is shifting to the full lifecycle: how a model changes after approval is becoming as important as how it performed at launch [2]. Second, regulators are not lowering premarket expectations to get there; the FDA’s 510(k) decision shows the bar stays in place even as new frameworks emerge [4]. WHO prequalification also opens a new route into procurement markets for AI tools that meet its bar [5]. With Japan’s comment window open until March [1] and MHRA guidance due by year-end [2], now is the moment to build change-management documentation and post-market performance monitoring into AI product plans, and to help shape the rules while they are still drafts. 

References 

1. PMDA Public comment on draft review points for medical devices using generative AI (18 Sep 2026): https://www.pmda.go.jp/review-services/drug-reviews/about-reviews/devices/0058.html 

2. MHRA / UK Government: Government backs recommendations of NHS doctors-led AI Commission (6 Oct 2026): https://www.gov.uk/government/news/government-backs-recommendations-of-nhs-doctors-led-ai-commission 

3. MHRA 2030 strategy to modernise patient-centred regulation for the era of AI and personalised medicines (14 Oct 2026): https://www.gov.uk/government/news/mhra-2030-strategy-to-modernise-patient-centred-regulation-for-the-era-of-ai-and-personalised-medicines 

4. FDA Final order, Exemption from Premarket Notification: radiology computer-aided detection and/or diagnosis and triage software, petition denied (91 FR 58817, 17 Sep 2026): https://www.federalregister.gov/documents/2026/09/17/2026-19074/medical-devices-exemption-from-premarket-notification-radiology-computer-aided-detection-andor 

5. WHO announces expansion of prequalification programme for medical devices (25 Sep 2026): https://www.who.int/news/item/25-09-2026-who-announces-expansion-of-prequalification-programme-for-medical-devices 

6. HSA extends partnerships to speed access to health innovations across key markets in Africa, Malaysia and Saudi Arabia (17 Sep 2026): https://www.hsa.gov.sg/announcements/hsa-extends-partnerships-speed-access/ 

7. NMPA signs letter of intent for cooperation with UK’s MHRA (30 Sep 2026): https://english.nmpa.gov.cn/2026-09/30/c_1217123.htm